Present survival analysis revealed that RRM2, one of the hub genes in the coexpression network, was associated with the prognosis of GBM patients; patients with high expression of RRM2 showed shorter overall survival time than those with low expression level. This evidence concerns the gene RRM2 and glioblastoma.